These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Chong V Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120 [TBL] [Abstract][Full Text] [Related]
28. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Kaiser PK Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860 [TBL] [Abstract][Full Text] [Related]
29. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Lu F; Adelman RA Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):171-7. PubMed ID: 18781316 [TBL] [Abstract][Full Text] [Related]
30. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620 [TBL] [Abstract][Full Text] [Related]
31. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Abouammoh M; Sharma S Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262 [TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic therapy in neovascular age-related macular degeneration. Lin RC; Rosenfeld PJ Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677 [No Abstract] [Full Text] [Related]
33. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807 [TBL] [Abstract][Full Text] [Related]
34. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Dadgostar H; Waheed N Eye (Lond); 2008 Jun; 22(6):761-7. PubMed ID: 18388961 [TBL] [Abstract][Full Text] [Related]
35. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Abrams P Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187 [TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF therapy: riding the wave of change. Hunyor AP Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912 [No Abstract] [Full Text] [Related]
38. [Introduction to the topic: anti-VEGF therapy in the management of AMD]. Meyer CH Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843 [No Abstract] [Full Text] [Related]
39. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration]. Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689 [TBL] [Abstract][Full Text] [Related]
40. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]